PACB - Pacific Biosciences of California, Inc.
| Previous Close | 5.51 |
| Open | 5.54 |
| Bid | 5.45 x 3200 |
| Ask | 5.90 x 2900 |
| Day's Range | 5.50 - 5.68 |
| 52 Week Range | 3.90 - 7.84 |
| Volume | 685,285 |
| Avg. Volume | 1,599,073 |
| Market Cap | 850.485M |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.63 |
- Zacks
Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
Merger or Not, Pacific Biosciences Needs to Deliver
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
- Zacks
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
- Zacks
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
What Happens If Pacific Biosciences Isn't Acquired By Illumina?
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
- Motley Fool
Why J.C. Penney, QEP Resources, and Pacific Biosciences Slumped Today
Bad news on several different fronts held these stocks back.
- Motley Fool
Here's Why Pacific Biosciences Is Tumbling Today
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
- Motley Fool
Why Illumina Stock Jumped 20% in June
The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved.
- Zacks
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
- Insider Monkey
Here’s What Hedge Funds Think About Pacific Biosciences of California, Inc. (PACB)
We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Pacific Biosciences of California, Inc. (NASDAQ:PACB). Pacific […]
- Zacks
46 and You: Genetic Testing = Giant Growth Market
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
- TheStreet.com
Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal
In early November the companies said Illumina, the San Diego provider of DNA-sequencing technologies for research and clinical use, agreed to pay $8 a share for its Menlo Park, California, rival. The deal's enterprise value is $1.2 billion. Early in Wall Street trading, Pacific Biosciences shares fell 3% to $6.48.
- GlobeNewswire
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants
MENLO PARK, Calif., June 13, 2019 -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left.
- Zacks
Pacific Biosciences (PACB) Down 7.8% Since Last Earnings Report: Can It Rebound?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
- GlobeNewswire
Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results
MENLO PARK, Calif., May 03, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2019, as.
- Zacks
Will Pacific Biosciences of California (PACB) Report Negative Q1 Earnings? What You Should Know
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Pacific Biosciences Launches New Sequel II System, Featuring ~8 Times the DNA Sequencing Data Output
New system is ideally suited for comprehensive variant detection, large genome de novo assembly, human structural variant characterization, whole transcriptome analysis, and.
- Insider Monkey
Nancy Havens’ Havens Advisors’ Return, AUM, and Holdings (Part II)
Read the beginning of this article here. Among the biggest Havens Advisors fourth quarter holdings that weren’t sold out in the meantime was Red Hat Inc (NYSE:RHT), a software company which offers a variety of open-source products, such as high performing Linux, container, cloud, and Kubernetes technologies. The fund purchased 70,324 Red Hat’s shares, establishing […]
- Motley Fool
Pump the Brakes on the Illumina and Pacific Biosciences Deal
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
- GlobeNewswire
Transplant Matches Identified by Ultra-High-Resolution HLA Typing Associated with Higher Patient Survival Rates
Pacific Biosciences of California, Inc. (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that a retrospective study conducted by scientists at the Anthony Nolan Research Institute in the UK demonstrated that ultra-high-resolution HLA typing performed with PacBio® sequencing identified stronger matches associated with improved survival rates among patients who received hematopoietic cell transplants. The study was published open access yesterday in the Journal of Biology of Blood and Marrow Transplantation.
- Zacks
Pacific Biosciences (PACB) Up 3.8% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Latest PacBio Sequencing Advancements Including Preview of Sequel II System to be Featured at Annual AGBT Conference
MENLO PARK, Calif., Feb. 26, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and.
